NasdaqGM:MSON

Stock Analysis Report

Executive Summary

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Misonix has significant price volatility in the past 3 months.
  • Misonix is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Misonix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.4%

MSON

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

4.1%

MSON

9.5%

US Medical Equipment

1.1%

US Market

MSON underperformed the Medical Equipment industry which returned 9.9% over the past year.

MSON outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

MSONIndustryMarket
7 Day-4.4%0.7%-0.2%
30 Day-13.5%0.1%2.5%
90 Day-27.5%2.5%1.6%
1 Year4.1%4.1%10.4%9.5%3.4%1.1%
3 Year246.6%246.6%69.3%64.1%45.2%35.8%
5 Year59.0%59.0%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Misonix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

5 months ago | Simply Wall St

How Much Of Misonix, Inc. (NASDAQ:MSON) Do Insiders Own?

Valuation

Is Misonix undervalued based on future cash flows and its price relative to the stock market?

8.16x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Misonix to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Misonix to establish if it is available at substantial discount.


Price Based on Earnings

Misonix is loss making, we can't compare its value to the US Medical Equipment industry average.

Misonix is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Misonix, we can't assess if its growth is good value.


Price Based on Value of Assets

Misonix is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Misonix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

72.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Misonix's revenue is expected to grow significantly at over 20% yearly.

Misonix's earnings are expected to grow significantly at over 20% yearly.

Misonix's revenue growth is expected to exceed the United States of America market average.

Misonix's earnings growth is expected to exceed the United States of America market average.

Misonix's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Misonix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Misonix performed over the past 5 years?

-63.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Misonix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Misonix's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Misonix's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Misonix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Misonix has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Misonix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Misonix's financial position?


Financial Position Analysis

Misonix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Misonix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Misonix has no debt.

Misonix has not taken on any debt in the past 5 years.


Balance Sheet

High level of physical assets or inventory.

Misonix has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Misonix has sufficient cash runway for 1.7 years based on current free cash flow.

Misonix has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 50.4% each year.


Next Steps

Dividend

What is Misonix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Misonix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Misonix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Misonix has not reported any payouts.

Unable to verify if Misonix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Misonix has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Misonix's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Stavros Vizirgianakis (49yo)

2.8yrs

Tenure

US$554,153

Compensation

Mr. Stavros George Vizirgianakis, B.Com., has been the Chief Executive Officer and President of Misonix, Inc. since December 19, 2016. Mr. Vizirgianakis served as an Interim Chief Executive Officer and Int ...


CEO Compensation Analysis

Stavros's remuneration is lower than average for companies of similar size in United States of America.

Stavros's compensation has increased whilst company is loss making.


Management Age and Tenure

2.9yrs

Average Tenure

52yo

Average Age

The tenure for the Misonix management team is about average.


Board Age and Tenure

5.0yrs

Average Tenure

55yo

Average Age

The tenure for the Misonix board of directors is about average.


Insider Trading

More shares have been bought than sold by Misonix individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$10,38921 Aug 19
Sharon Klugewicz
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares500
Max PriceUS$20.78
BuyUS$2,26017 Jun 19
Sharon Klugewicz
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares90
Max PriceUS$25.11
BuyUS$11,78704 Jun 19
Joseph Dwyer
EntityIndividual
Role
Chief Financial Officer
CFO, Treasurer & Secretary
Shares500
Max PriceUS$24.09
SellUS$19,44712 Feb 19
Joseph Brennan
EntityIndividual
Shares1,000
Max PriceUS$19.45
BuyUS$5,41416 Nov 18
Joseph Dwyer
EntityIndividual
Role
Chief Financial Officer
CFO, Treasurer & Secretary
Shares350
Max PriceUS$15.47

Ownership Breakdown


Management Team

  • Joe Dwyer (63yo)

    CFO, Treasurer & Secretary

    • Tenure: 3yrs
    • Compensation: US$821.87k
  • Robert Ludecker (52yo)

    Senior Vice President of Global Sales & Marketing

    • Tenure: 4.3yrs
    • Compensation: US$695.82k
  • Stavros Vizirgianakis (49yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$554.15k
  • Sharon Klugewicz (51yo)

    Chief Operating Officer

    • Tenure: 0.5yrs
    • Compensation: US$814.88k
  • John Salerno (64yo)

    VP of Quality and Regulatory Affairs & Chief Compliance Officer

    • Tenure: 0yrs

Board Members

  • Tom Patton (55yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$167.72k
  • Pat McBrayer (67yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: US$157.72k
  • Gwen Watanabe (48yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$191.01k
  • Charles Miner (68yo)

    Independent Director

    • Tenure: 14.7yrs
    • Compensation: US$157.72k
  • Stavros Vizirgianakis (49yo)

    President

    • Tenure: 2.8yrs
    • Compensation: US$554.15k

Company Information

Misonix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Misonix, Inc.
  • Ticker: MSON
  • Exchange: NasdaqGM
  • Founded: 1959
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$177.254m
  • Shares outstanding: 9.65m
  • Website: https://www.misonix.com

Number of Employees


Location

  • Misonix, Inc.
  • 1938 New Highway
  • Farmingdale
  • New York
  • 11735
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MSONNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1992
MX9DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992

Biography

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company offers BoneScalpel,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:19
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.